8-K - Lite Strategy, Inc. (0001262104) (Filer)
Published . Updated .
Key takeaways
- 8-K - Lite Strategy filed an 8-K with the SEC on Nov 3 (a notice of a material company event).
- Exposed: LITS
- Market reaction: LITS −8.2% after three sessions
Market Call
Think this story will push the stock up or down over the next three trading days? Make a free call and see what other readers think. Points are play money with no cash value.
Get these market calls by email
The week's biggest market-moving stories, Congress trades and Trump posts, with the tickers they touch. Free, one email a week.
Free. We only use your email to send the digest, never sell or share it, and every email has a one-click unsubscribe link. See our privacy policy.
8-K - Lite Strategy filed an 8-K with the SEC on Nov 3 (a notice of a material company event).
Directly affected
- LITS Lite Strategy-33.6% 17d
Named in this report.
Indirectly affected
- XLV Health Care Select Sector SPDR
Health Care Select Sector SPDR holds the health sector that Lite Strategy belongs to, so it often moves with news about it.
- LLY Eli Lilly and+25.1% 30d
Eli Lilly and is a peer of Lite Strategy in pharmaceutical preparations; rivals often move on the same news.
- JNJ Johnson & Johnson+12.1% 30d
Johnson & Johnson is a peer of Lite Strategy in pharmaceutical preparations; rivals often move on the same news.
- ABBV AbbVie+12.0% 30d
AbbVie is a peer of Lite Strategy in pharmaceutical preparations; rivals often move on the same news.
- MRK Merck+3.5% 30d
Merck is a peer of Lite Strategy in pharmaceutical preparations; rivals often move on the same news.
- ABT Abbott Laboratories+10.0% 30d
Abbott Laboratories is a peer of Lite Strategy in pharmaceutical preparations; rivals often move on the same news.
Price reaction, T-5 to T+3
| Ticker | T-5 | T-3 | T-1 | T0 | T+1 | T+2 | T+3 |
|---|---|---|---|---|---|---|---|
| LITS | +17.87% | +7.73% | base | +4.83% | -6.28% | -1.93% | -8.18% |
| XLV | -2.42% | +0.36% | base | +3.08% | +0.65% | +0.47% | +2.39% |
| LLY | -8.25% | +0.73% | base | +0.62% | -2.48% | -3.88% | +0.21% |
| JNJ | +2.19% | +2.93% | base | +3.82% | +2.34% | +3.82% | +5.99% |
| ABBV | +0.42% | +3.41% | base | +2.66% | +1.15% | +1.97% | +2.59% |
| MRK | -1.72% | +4.16% | base | +3.94% | +1.84% | +1.45% | +2.81% |
| ABT | -5.79% | -2.52% | base | +5.93% | +3.79% | +0.53% | +1.02% |
Closing-price change versus T-1, the last close before the story. T0 to T+3 fill in after each market close. Prices: Alpaca IEX.
Filed: 2026-11-03 AccNo: 0001193125-26-445292 Size: 150 KB Item 3.02: Unregistered Sales of Equity Securities
Source: sec-edgar
Lite Strategy (LITS) since “8-K - Lite Strategy, Inc. (0001262104) (Filer),” compared with the market
Since the first closing price after “8-K - Lite Strategy, Inc. (0001262104) (Filer),” Lite Strategy (LITS) is -16.75%.
| Company | When | Move | Status |
|---|---|---|---|
| ABBV | that day | +2.66% | final price |
| ABBV | the next day | +1.15% | final price |
| ABBV | two days later | +1.97% | final price |
| ABBV | three days later | +2.59% | final price |
| ABBV | three days earlier | +3.41% | final price |
| ABBV | five days earlier | +0.42% | final price |
| ABT | that day | +5.93% | final price |
| ABT | the next day | +3.79% | final price |
| ABT | two days later | +0.53% | final price |
| ABT | three days later | +1.02% | final price |
| ABT | three days earlier | -2.52% | final price |
| ABT | five days earlier | -5.79% | final price |
| JNJ | that day | +3.82% | final price |
| JNJ | the next day | +2.34% | final price |
| JNJ | two days later | +3.82% | final price |
| JNJ | three days later | +5.99% | final price |
| JNJ | three days earlier | +2.93% | final price |
| JNJ | five days earlier | +2.19% | final price |
| Lite Strategy (LITS) | that day | +4.83% | final price |
| Lite Strategy (LITS) | the next day | -6.28% | final price |
| Lite Strategy (LITS) | two days later | -1.93% | final price |
| Lite Strategy (LITS) | three days later | -8.18% | final price |
| Lite Strategy (LITS) | three days earlier | +7.73% | final price |
| Lite Strategy (LITS) | five days earlier | +17.87% | final price |
| LLY | that day | +0.62% | final price |
| LLY | the next day | -2.48% | final price |
| LLY | two days later | -3.88% | final price |
| LLY | three days later | +0.21% | final price |
| LLY | three days earlier | +0.73% | final price |
| LLY | five days earlier | -8.25% | final price |
| MRK | that day | +3.94% | final price |
| MRK | the next day | +1.84% | final price |
| MRK | two days later | +1.45% | final price |
| MRK | three days later | +2.81% | final price |
| MRK | three days earlier | +4.16% | final price |
| MRK | five days earlier | -1.72% | final price |
| XLV | that day | +3.08% | final price |
| XLV | the next day | +0.65% | final price |
| XLV | two days later | +0.47% | final price |
| XLV | three days later | +2.39% | final price |
| XLV | three days earlier | +0.36% | final price |
| XLV | five days earlier | -2.42% | final price |
Congressional trades in the stocks in this story
- Rep. Gilbert Cisneros bought Eli Lilly (LLY), worth $1,001 - $15,000 on 20 Oct 2026. That is 14 days before publication. Filed 10 Nov 2026. View the filing.
- Rep. Rohit Khanna bought Eli Lilly (LLY) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 60 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Rohit Khanna sold Johnson & Johnson (JNJ) (held by a spouse), worth $15,001 - $50,000 on 7 Oct 2026. That is 27 days before publication. Filed 5 Nov 2026. View the filing.
- Rep. Thomas H. Kean Jr sold Johnson & Johnson (JNJ), worth $1,001 - $15,000 on 30 Sep 2026. That is 34 days before publication. Filed 30 Oct 2026. View the filing.
- Rep. Rohit Khanna bought Johnson & Johnson (JNJ) (held by a spouse), worth $1,001 - $15,000 on 25 Sep 2026. That is 39 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Rohit Khanna bought AbbVie (ABBV) (held by a spouse), worth $1,001 - $15,000 on 7 Oct 2026. That is 27 days before publication. Filed 5 Nov 2026. View the filing.
- Rep. Pete Sessions sold AbbVie (ABBV), worth $15,001 - $50,000 on 14 Sep 2026. That is 50 days before publication. Filed 18 Sep 2026. View the filing.
- Rep. Rohit Khanna sold AbbVie (ABBV) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 60 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Maria Elvira Salazar sold Merck (MRK), worth $1,001 - $15,000 on 24 Sep 2026. That is 40 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Maria Elvira Salazar bought Merck (MRK), worth $15,001 - $50,000 on 19 Aug 2026. That is 76 days before publication. Filed 9 Sep 2026. View the filing.
- Rep. Rohit Khanna bought Abbott Laboratories (ABT) (held by a spouse), worth $1,001 - $15,000 on 7 Oct 2026. That is 27 days before publication. Filed 5 Nov 2026. View the filing.
- Rep. Pete Sessions sold Abbott Laboratories (ABT) (held by a spouse), worth $50,001 - $100,000 on 2 Oct 2026. That is 32 days before publication. Filed 27 Oct 2026. View the filing.
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
Who is named in “8-K - Lite Strategy, Inc. (0001262104) (Filer)”
Companies mentioned with this story
- LITS Lite Strategy
In “8-K - Lite Strategy, Inc. (0001262104) (Filer),” Lite Strategy (LITS) is linked, with no stored direction, high confidence. Reason on file: SEC 8-K filing -> direct issuer disclosure -> LITS
How “8-K - Lite Strategy, Inc. (0001262104) (Filer)” reaches Lite Strategy (LITS)
Lite Strategy (LITS) is the company in “8-K - Lite Strategy, Inc. (0001262104) (Filer),” the 3 Nov 2026 this story story.
The link for Lite Strategy (LITS) is this: SEC 8-K filing -> direct issuer disclosure -> LITS
Dates in the story, and the Lite Strategy (LITS) price range
LITS traded between 0.90 and 1.54 across 20 sessions. The latest close on file is 0.90.
How solid “8-K - Lite Strategy, Inc. (0001262104) (Filer)” looks
14 out of 100
“8-K - Lite Strategy, Inc. (0001262104) (Filer)” scores 14 out of 100. The score uses 1 sources, and 1 linked companies.